Kymera Investor Day Presentation Deck

KT-333 Accelerated and Full Approval Strategies Across Several Indications ≥2nd Line R/R PTCL (or CTCL)- KT-333 monotherapy First US Approval [Accelerated] (Phase 2 single arm study) KYMERA 1st Line PTCL (or CTCL)- KT-333 monotherapy or combo with SOC FULL Approval (Phase 3 Study) ©2021 KYMERA THERAPEUTICS, INC. LGL-L KT-333 monotherapy FULL Approval (Phase 2 single arm study) KYMERA R&D DAY - December 16th, 2021 Solid Tumor CRC MSI-H (e.g.) – PD1 inhibitor refractory KT-333 + PD1 inhibitor FULL Approval (Phase 2/3 randomized study) 1st Line KT-333 combo with PD-1 inhibitor FULL Approval (Phase 3 Study) PAGE 65

View entire presentation